WallStreet Research Updates Coverage of Nymox Pharmaceutical Corporation Shares with Speculative Buy Recommendation at www.WallStreetResearch.org.HASBROUCK HEIGHTS, N.J. -- Nymox Pharmaceutical Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : NYMX NYMX New York Mercantile Exchange ) announced today that WallStreet Research has released an updated analyst report covering the Company's shares with a speculative buy recommendation. The report on Nymox Pharmaceutical and additional information about WallStreet Research is available at www.WallStreetResearch.org. WallStreet Research is a prominent research boutique led by Alan Stone, Managing Director of Alan Stone & Company, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control ("ASC ASC Ambulatory surgery center, see there "). The firm specializes in the microcap and smallcap investment arena, looking for Looking for In the context of general equities, this describing a buy interest in which a dealer is asked to offer stock, often involving a capital commitment. Antithesis of in touch with. emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength, and outstanding long-term earnings growth possibilities. Mr. Stone was formerly a securities analyst and assistant portfolio manager at Merrill Lynch Asset Management and an investment analyst at Prudential Insurance Company's Capital Markets Group. The firm has offices in Los Angeles, CA, Palm Beach, FL, and New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , NY, and is well known for discovering undervalued companies and bringing them to the attention of the investment community. ASC/WSR also arranges roadshows for its publicly traded clients, before the investment community in New York City, California, and Florida. According to the report "with no long-term debt Long-Term Debt Loans and financial obligations lasting over one year. Notes: For example debts obligations such as bonds and notes which have maturities greater than one year would be considered long-term debt. and a low burn rate compared to industry standards, especially considering the number of marketed products and significant projects in the pipeline, the Company appears to be an excellent buying opportunity." Nymox Pharmaceutical Corporation is a biotechnology company engaged in development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. The Company is conducting pivotal Phase II clinical trials for NX-1207 a drug for benign prostatic hyperplasia benign prostatic hyperplasia n. Abbr. BPH A nonmalignant enlargement of the prostate gland commonly occurring in men after the age of 50, and sometimes leading to compression of the urethra and obstruction of the flow of urine. (BPH BPH abbr. benign prostatic hyperplasia BPH Benign prostatic hypertrophy, a very common noncancerous cause of prostatic enlargement in older men. ). Nymox has a number of drugs in development for E. coli E. coli: see Escherichia coli. E. coli in full Escherichia coli Species of bacterium that inhabits the stomach and intestines. E. coli can be transmitted by water, milk, food, or flies and other insects. infection, Alzheimer's disease, oncology, and infectious disease. The Company markets NicAlert(TM) and TobacAlert( TM) tests for measuring tobacco product exposure. Nymox offers AlzheimAlert(TM), a test to aid in the diagnosis of Alzheimer's disease. Additional information regarding Nymox Pharmaceutical is available on the company's Web site at www.nymox.com, email: info@nymox.com, or at (800) 936-9669, and in the WallStreet Research report at www.WallStreetResearch.org. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities. The information presented in the WallStreet Research report is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities referred to herein or otherwise. Readers are encouraged to conduct their own due diligence and review all of the company's financial statements and risks statements on file with the SEC. Nymox Pharmaceutical Corporation has paid a fee to Alan Stone & Company, LLC in conjunction with the preparation and distribution of this report, the terms of which are disclosed in full in the report and on the website at www.WallStreetResearch.org. Alan Stone & Company, LLC or its associates may own shares, for investment purposes, in its corporate accounts, and may increase or decrease its positions at any time, without notice. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion